Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$110.45 USD

110.45
389,055

+0.42 (0.38%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $110.46 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

JAZZ or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason

by Zacks Equity Research

Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason

Is Jazz (JAZZ) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Urmimala Biswas headshot

5 Best PEG Stocks Suitable for GARP Investors

by Urmimala Biswas

While P/E alone only gives an idea of stocks that are trading at a discount, PEG, while adding the growth element to it, helps to identify stocks that have solid potential.

BioCryst Down Despite Hereditary Angioedema Study Meets Goal

by Zacks Equity Research

BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.

JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

JAZZ vs. PCRX: Which Stock Is the Better Value Option?

Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates

by Zacks Equity Research

So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.

3 Reasons Why Growth Investors Shouldn't Overlook Jazz (JAZZ)

by Zacks Equity Research

Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.

Jazz Pharmaceuticals (JAZZ) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of 16.14% and 7.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

3 Reasons Why Jazz (JAZZ) Is a Great Growth Stock

by Zacks Equity Research

Jazz (JAZZ) could produce exceptional returns because of its solid growth attributes.

Concert Pharma Initiates Early-Stage Schizophrenia Study

by Zacks Equity Research

Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.

Jazz (JAZZ) Down 0.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.

Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision

by Zacks Equity Research

The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.

Is Jazz Pharmaceuticals (JAZZ) a Good Value Investor Pick?

by Zacks Equity Research

Let's see if Jazz Pharmaceuticals (JAZZ) stock is a good choice for value-oriented investors right now from multiple angles.

The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom

Tirthankar Chakraborty headshot

The Best And Worst Stocks of the 10-Year Bull Market

by Tirthankar Chakraborty

We highlight some of the best and worst stocks over the bull market's 10 years.

Jazz Pharmaceuticals (JAZZ) Surges: Stock Moves 7.9% Higher

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Jazz Pharma (JAZZ) Q4 Earnings & Sales Beat, Stock Up 8%

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) surpasses earnings and sales estimates in the fourth quarter and issues a solid outlook for 2019. Shares rise 8% in after-hours trading.